- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07935980
Intradialytic Benson's Relaxation Technique in Patients With Chronic Kidney Disease
Intradialytic Benson's Relaxation Technique on Dialysis Adequacy and Sleep Quality in Patients With Chronic Kidney Disease
The purpose of this study is to determine the impact of benson's relaxation technique on dialysis adequacy and sleep quality among CKD patients.
The intervention will include intradialytic benson's relaxation sessions, and outcomes such dialysis adequacy and sleep quality will be evaluated after 12 weeks of benson's relaxation technique in patients with CKD.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A major public health concern, chronic kidney disease is characterized by abnormalities of kidney structure or function that have been present for more than three months and have particular health consequences . Uremia is a clinical condition associated with declining renal function and is characterized by fluid overload, electrolyte imbalances, metabolic abnormalities, and physiological changes. Urea exhibits direct and indirect toxicity to various tissues leading to symptoms such as nausea, vomiting, fatigue, anorexia, muscle cramps, pruritus, and altered mentation.Previous studies reported that poor sleep is one of the most prevalent symptoms experienced by CRD patients most patients because of increase toxins concentrations of plasma (creatinine and urea), anemia, nocturnal hypoxia, and co-morbidities. Benson's relaxation technique is an effective intervention which has been introduced as useful non-pharmacological method which decreases stress over its effect on mental, physical conditions, depression, anxiety, self-steam, enhance sleep and improves the quality of life of hemodialysis patients.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Manar Tarek Mostafa Morsy, BSc in physical therapy
- Phone Number: +0201200469648
- Email: drmtarekmali@gmail.com
Study Locations
-
-
-
Cairo, Egypt
- Recruiting
- Quweisna central hospital
-
Contact:
- Manar Tarek Mostafa Morsy, BSc in physical therapy
- Phone Number: +201200469648
- Email: drmtarekmali@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients of both sexes diagnosed with ESRD (stage 5 CKD).
- Ages from 40 to 60 years.
- Patients on hemodialysis for at least one year with 2 to 3 sessions per week lasting 3 to 4 hours each.
- Their body mass index 25 - 34.9 kg/ m2 and under medical supervision.
- They are receiving HD though an uncomplicated arm arteriovenous (AV) fistula.
- They are in a stable medical, clinical and hemodynamic status.
- Individuals don't require lower limb dialysis grafting.
Exclusion Criteria:
-
1- Patients with resting systolic blood pressure more than 200 mm Hg & or diastolic blood pressure greater than 120 mm Hg.
2- Patients with uncontrolled diabetes mellitus, peripheral neuropathy, hepatic disorders (hepatic cancer, hepatitis) and infectious illness (HIV / AIDS).
3- Patients with mental health problems and cognitive impairment owing to the inability to educate them how to perform relaxation techniques.
4- Any patient who missed more than two weeks of the program or want to terminate the program.
5- Severe Obesity (BMI> 35). 6- Patients had a previous history of psychiatric disorders. 7- Uncontrolled pulmonary disease (e.g. exaggerated acute asthma, exaggerated acute chronic obstructive lung disease).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Study group (benson's relaxation technique)
Thirty patients of both gender will receive Benson's relaxation technique 3 times / week for 12 weeks with duration 10-20 minutes at the end of second hour of dialysis session and aerobic exercise in addition to their medical treatment. |
Research has shown that the Benson Relaxation Technique (BRT) is an effective strategy for decreasing sleep disruptions in older persons and hemodialysis patients with hypertension focuses on deep rhythmic breathing and mental focusing rather than physical muscle tensing. Steps : 1. Find a quiet environment: Sit or lie down in a comfortable, quiet space where you will not be disturbed. 2. Close your eyes: Gently close your eyes to block out visual distractions.3. Relax your muscles: Release all tension from your body, moving progressively from your feet up to your face (or top of your head).4. Breathe through your nose: Become aware of your natural breathing. As you exhale, silently repeat a chosen focus word or phrase-such as "one", "calm", or "peace"-to yourself (e.g., inhale... exhale, "one").5. Maintain a passive attitude: When distracting thoughts drift into your mind, do not fight them or judge yourself.6.Practice for 10 to 20 minutes7.Transition slowly |
|
Active Comparator: Control group
Thirty patients of both gender will receive the same aerobic exercise in addition to their medical treatment. Aerobic exercise: by using mini pedal bike for 12 weeks , 30 minutes in the first 2 hours of dialysis session |
Aerobic ex by using mini pedal exerciser without involving benson's relaxation technique. for 12 weeks , 30 minutes in the first 2 hours of dialysis session |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Dialysis adequacy
Time Frame: 12 weeks
|
Dialysis adequacy will be assessed using URR (Urea Reduction Ratio) and KT/V measured pre- and post-intervention to determine the effectiveness of the treatment in improving hemodialysis efficiency. |
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Sleep Quality Measured by the Pittsburgh Sleep Quality Index (PSQI)
Time Frame: 12 weeks
|
Sleep Quality will be assessed by PSQI pre and post intervention to determine the effectiveness of (sleep latency, sleep duration, sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction) |
12 weeks
|
|
Change in Anxiety Score Measured by the Hospital Anxiety and Depression Scale (HADS)
Time Frame: 12 weeks
|
Anxiety symptoms will be assessed using the anxiety subscale of the Hospital Anxiety and Depression Scale (HADS-A). Changes in anxiety scores will be compared between baseline and follow-up. |
12 weeks
|
|
Change in Depression Score Measured by the Hospital Anxiety and Depression Scale (HADS)
Time Frame: 12 weeks
|
Depressive symptoms will be assessed using the depression subscale of the Hospital Anxiety and Depression Scale (HADS-D). Changes in depression scores will be compared between baseline and follow-up. |
12 weeks
|
|
Change in Systolic and Diastolic Blood Pressure
Time Frame: 12 weeks
|
Systolic and diastolic blood pressure will be measured using a digital sphygmomanometer to assess changes in blood pressure following the intervention. |
12 weeks
|
|
Change in Functional Performance Measured by the 2-Minute Walk Test (2MWT)
Time Frame: 12 weeks
|
Functional performance will be assessed using the 2-Minute Walk Test (2MWT), measured by the distance walked in meters during two minutes. |
12 weeks
|
|
Change in Kidney Disease Quality of Life (KDQOL-36) Scores
Time Frame: 12 weeks
|
Health-related quality of life will be assessed using the Kidney Disease Quality of Life 36-item Short Form survey (KDQOL-36), including its kidney disease-specific and generic health-related quality-of-life domains. |
12 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P.T.REC/012/006439
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.